You are here: Industry Insights > Brilacidin

News List

Innovation’s drug shows antiviral activity against Covid-19 in study pharmaceutical-technology
July 23, 2021
Innovation Pharmaceuticals has reported that its drug candidate, Brilacidin, showed broad-spectrum antiviral activity against Covid-19 in an in vitro study.
Innovation Pharma closes enrolment in Phase II Covid-19 drug trial pharmaceutical-technology
June 04, 2021
Innovation Pharmaceuticals has completed subject enrolment in Phase II clinical trial of its drug candidate, Brilacidin, for treating hospitalised patients with moderate-to-severe Covid-19.
Innovation Pharma to increase dosing frequency in Covid-19 drug trial pharmaceutical-technology
April 07, 2021
Innovation Pharmaceuticals is set to increase dosing frequency in Phase II clinical trial of a drug candidate, Brilacidin, for treating moderate-to-severe Covid-19 in hospitalised patients.
Innovation’s Brilacidin shows promise in-vitro against Covid-19 pharmaceutical-technology
August 26, 2020
Innovation Pharmaceuticals has reported promising data from ongoing in-vitro testing of its Brilacidin at a US Regional Biocontainment Laboratory (RBL) to treat Covid-19.